LevelJump Announces Q2 Record Revenue
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce its financial results for the second quarter ended June 30, 2026. The Company, through its CTS and ADC operations, had a strong quarter as demand continued increasing for our services. Our current focus remains on organic growth, expansion of services, and maximizing revenue opportunities. Financial and Operationa
Healthcare and Hospitals, Health
2026-08-24 7:30 PM EDT | LevelJump Healthcare Corp.
Theralase(R) Closes C$3.6 Million Brokered Financing
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering")
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-24 5:01 PM EDT | Theralase Technologies Inc.
NorthPalm Commits Entire Cybeats Position to a 12-Month Lock-Up; 60 Million Shares Representing Approximately 30% of Cybeats
Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm" or the "Company"), is pleased to announce that it has committed to a 12-month lock-up of its entire remaining position of 60,000,000 common shares of Cybeats Technologies Corp. (CSE: CYBT) ("Cybeats"), representing approximately 30% of Cybeats' outstanding shares. NorthPalm remains the largest institutional shareholder of Cybeats and is committed to maintaining a signif
Biotechnology, Healthcare and Hospitals, Health
2026-08-24 9:39 AM EDT | NorthPalm Capital Corp.
Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting
Winter Park, Florida--(Newsfile Corp. - August 24, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced that it has entered into an engagement letter with Lucosky Brookman LLP ("Lucosky Brookman") to act as legal counsel in connection with the Company's planned uplisting from the OTC Markets to the NASDAQ Capital Market.
Healthcare and Hospitals, Health
2026-08-24 8:00 AM EDT | Adia Med Inc.
WELL Health Redeems $70 Million 5.50% Convertible Debentures
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, r
Technology, Computer Software, Healthcare and Hospitals, Health
2026-08-20 6:30 AM EDT | WELL Health Technologies Corp.
Relief AI Inc. Announces Closing of Brokered Private Placement of Subscription Receipts
Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Relief AI Inc. ("Relief AI" or the "Company") and 1329308 B.C. Ltd. ("132 BC") jointly announce that, further to the joint press releases of July 6, 2026 and July 30, 2026, the Company has closed its "best efforts" brokered private placement through the issuance of 5,723,900 subscription receipts of the Company (each, a "Subscription Receipt") at a price of $1.00 per Subscription Receipt (the "Offering Price
Technology, Healthcare and Hospitals, Health
2026-08-19 9:09 AM EDT | Relief AI Inc.
Obesity Medicine Association Announced as Primary Educational Partner of the American Board of Obesity Medicine
Denver, Colorado--(Newsfile Corp. - August 19, 2026) - The Obesity Medicine Association (OMA) is honored to announce that they have been named one of the first Primary Educational Partners (PEPs) of the American Board of Obesity Medicine (ABOM). PEPs are organizations approved by ABOM to offer Core Obesity Medicine CME credit to physicians applying for obesity medicine certification through their Continuing Medical Education (CME) pathway. The partnership program was designed as
Healthcare and Hospitals, Health
2026-08-19 9:00 AM EDT | Obesity Medicine Association
Illumisoft Appoints Ehsan Agahi as CEO, Commences Trading on OTCQB Venture Market, Announces Shares for Debt Settlement
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) ("Illumisoft" or the "Company") today announced that Ehsan Agahi, currently Executive Chairman of the Company, has been appointed Chief Executive Officer, effective August 19, 2026. Mr. Agahi will continue to serve as Chairman of the Board. As Executive Chairman since the completion of the Company's qualifying transaction, Mr. Agahi has been closely involved in Illumiso
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-08-19 7:18 AM EDT | Illumisoft Lighting Corp.
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platform The broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi,
Technology, Healthcare and Hospitals
2026-08-19 6:30 AM EDT | HEALWELL AI
Richards Group Inc. Announces August 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended August 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on August 31, 2026 and will be payable on September 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-08-18 11:12 AM EDT | Richards Group Inc.
Shoppers Drug Mart Helps Canadians Access Personalized Weight Management Support, Developed in Collaboration with Launchit Solutions
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - Shoppers Drug Mart has introduced a Weight Management Program, a free, virtual service designed to help eligible Canadians access personalized support for weight management and obesity care. The Weight Management Program is a free, online-only personalized service available in participating provinces that helps Canadians reach their weight management goals through virtual access to nurse practitioners and dietitians, as well as supp
Technology, Computer Software, Healthcare and Hospitals
2026-08-18 9:30 AM EDT | Launchit Solutions Inc.
Alzai Health Corp. Announces Marketing Services Agreement
Toronto, Ontario--(Newsfile Corp. - August 17, 2026) - Alzai Health Corp. (TSXV: ALZI) (the "Company" or "ALZAI") announces that it has entered into a services agreement dated August 12, 2026 (the "Services Agreement") with Euro Digital Media Ltd. ("Euro Digital") (address: 71-75 Shelton Street, Covent Garden, London, UK WC2H 9JQ) pursuant to which Euro Digital will provide market awareness and digital marketing services to the Company. Under the terms of the Services Agreement, Euro Di
Technology, Computer Software, Healthcare and Hospitals
2026-08-17 6:00 AM EDT | Alzai Health Corp.
Richards Group Inc. Announces Change of Auditor
Toronto, Ontario--(Newsfile Corp. - August 15, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") today announced that its Board of Directors (the "Board"), on the recommendation of the Audit Committee, has approved the appointment of Ernst & Young LLP, Chartered Professional Accountants ("Successor Auditor") as the Company's auditor, replacing PricewaterhouseCoopers LLP ("Former Auditor"), effective August 10, 2026. The change followed a review of the Company's external audit require
Healthcare and Hospitals, Household / Consumer / Cosmetics, Pharmaceuticals
2026-08-15 8:15 PM EDT | Richards Group Inc.
Aurora Spine Announces Settlement of Arbitration, New Patent License Agreement for SI Joint Product and Increase in Funding from Insider
Carlsbad, California--(Newsfile Corp. - August 14, 2026) - Aurora Spine Corporation (TSXV: ASG) ("Aurora Spine" or the "Company") announced today that it has entered into a new non-exclusive license to US patent #9,451,986 titled "Percutaneous sacroiliac joint implant and method for surgically inserting and securing the implant into the sacroiliac joint" in an agreement with SILIF Corporation of New York, New York ("SILIF"). The new patent license replaces a previous version
2026-08-14 5:00 PM EDT | Aurora Spine Corporation
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
Dublin, Ireland--(Newsfile Corp. - August 14, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that it will change its ticker symbol on the SIX Swiss Stock Exchange from “COPN” to “CMHC”. This change is expected to take effect at the opening of trading on Monday, August 17, 2026. The new ticker symbol,
Healthcare and Hospitals, Health
2026-08-14 1:22 AM EDT | Cosmo Pharmaceuticals N.V.
Kovo+ Announces Special Committee and Strategic Review Process
Calgary, Alberta--(Newsfile Corp. - August 13, 2026) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") announces that, further to its press release of August 6, 2026, the Company's board of directors (the "Board of Directors") has established a special committee of directors (the "Special Committee") to, among other things, lead the Company's evaluation of strategic and financing alternatives in connection with the default notice and demand for repayment
Technology, Healthcare and Hospitals, Internet Technology
2026-08-13 4:30 PM EDT | Kovo+ Holdings Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximately 19.5% as compared to the same period of the pri
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-13 4:11 PM EDT | Elite Pharmaceuticals, Inc.
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.
Healthcare and Hospitals, Health
2026-08-13 12:07 PM EDT | Adia Med Inc.
Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing
Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m. to both in-person students and those joining live online.
Healthcare and Hospitals, Health
2026-08-11 8:00 AM EDT | Adia Med Inc.
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894
King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based on its proprietary INTASYL® gene-silencing technology, today announced the receipt of a U.S. Notice of Allowance for a patent covering PH-894, further strengthening the Company's intellectual property portfolio. The patent allowance represents a critical milestone in protecting Phio's stra
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-11 7:00 AM EDT | Phio Pharmaceuticals Corp.